Effect of Pamidronate on Osteoporosis in Patients with β-Thalassemia Major
Authors
Abstract:
Background: β-thalassemia major is a hereditary life threatening anemia which requires regular blood transfusion. Clinical symptoms of the disease are growth retardation, pallor, jaundice and skeletal alternations. The variety of bone disease in thalassemia major is manifested by diffuse bone pain or deformity, spontaneous and pathologic fractures and osteopenia or osteoporosis. This study aimed to evaluate the effect of Pamidronate on beta thalassemia major induced osteoporosis. Patients and Methods: This cross sectional study was conducted on 20 patients with β-thalassemia major with osteoporosis. Patients received Pamidronate injections (30 mg in equal intervals of one month) for one year. At the beginning and the end of study period (after twelve months of treatment) patients’ BMD and Z score of lumbar spine and Hip were determined. Results: The mean baseline BMD of lumbar spine and hip among patients were 097/0±720/0(gr/cm²) and 083/0±684/0 (gr/cm²) respectively which at the end of the study these numbers reached to 100/0±783/0(gr/cm²) (p<0.001) and 097/0±713/0(gr/cm²) (p=0.015) respectively. The mean baseline Z score of lumbar spine and hip for patients were /0±98/2-956 and 727/0±96/1- before treatment (one full year of treatment) that reached 886/0±44/2- (p=0.001) and 856 /0±47/1- (p=0.003) respectively. The baseline alkaline phosphatase was 94/89±85/385 µg/dl and after treatment this value decreased to 66/113±95/251µg/dl (p<0.001). Conclusion: The Pamidronate is effective in increasing the bone mineral density and improving the osteoporosis condition in patients with β-thalassemia major. Keywords: Osteoporosis, BMD (Bone Mineral Density), β-thalassemia major, Pamidronate.
similar resources
effect of pamidronate on osteoporosis in patients with β-thalassemia major
background: β-thalassemia major is a hereditary life threatening anemia which requires regular blood transfusion. clinical symptoms of the disease are growth retardation, pallor, jaundice and skeletal alternations. the variety of bone disease in thalassemia major is manifested by diffuse bone pain or deformity, spontaneous and pathologic fractures and osteopenia or osteoporosis. this study aime...
full textEvaluation of relationship between biochemical parameters and osteoporosis in patients with β-thalassemia major
Background: Osteoporosis is one of the late complications of β-Thalassemia major. The pathogenesis of osteoporosis depends on different factors. Ineffectiveness of hematopoiesis is the major factor, and the other factors are defected by hormonal functions or biochemical parameters. Osteoclasts hyperactivity in thalassemia increases the serum receptor activator of nuclear factor Kappa B ligand (...
full textAnalysis of Survival in Patients with β-thalassemia Major in Guilan, Northern Iran
Background: Advances in treatment of thalassemia major (TM) have improved life expectancy and survival of the patients. This study was conducted to assess survival rate of these patients in Guilan province, Northern Iran. Methods: In this cross-sectional study, records of 1243 patients with TM from 2001 to March 2016 were evaluated in Guilan province. Sources of data were health centers of the...
full textEVALUATION OF PULMONARY IRON OVER LOAD IN PATIENTS WITH Β-THALASSEMIA MAJOR USING SPIROMETRY
Background & Aims: Spirometry changes in thalassemic patients can be obstructive or restrictive and pulmonary dysfunction depends on age and body iron overload. In this study the effectiveness of lung spirometry in detecting iron overload in patients with β-thalassemia was investigated. Materials & Methods: This cross-sectional (descriptive-analytic) study investigated the spirometry test resu...
full textTherapeutic approaches in patients with β-thalassemia
Beta-thalassemia (β-thal) is a congenital hemoglobinopathy explained by a decreased level (β+) or absence (βο) of β-globin gene expression. Microcytic hypochromic anemia and various clinical symptoms comprising severe anemia to clinically nonsymptomatic features. Treatment with an ordered blood transfusion and iron chelator agents can decrease transfusion iron overload that causes normal matura...
full textMy Resources
Journal title
volume 6 issue None
pages 149- 153
publication date 2014-05
By following a journal you will be notified via email when a new issue of this journal is published.
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023